The level of magnesium in the blood is an important factor in the immune system’s ability to tackle pathogens and cancer cells. Researchers have reported that T cells need a sufficient quantity of magnesium in order to operate efficiently. Their findings may have important implications for cancer patients.
Steroid estrogens play an important role as embryos develop a sense of smell, new research shows. The study, which examined zebrafish embryos, discovered a type of astrocyte glial cell that is new to science, and have been named estrogen responsive olfactory bulb (EROB) cells.
In a new study of the Zika virus, scientists have discovered a key mechanism used by the virus to evade the antiviral response of the cell it is attacking. This finding contributes to a better understanding of how viruses infect cells, overcome immune barriers and replicate — information that is essential for fighting them.
Researchers have identified a new mechanism by which a protein known for repairing damaged DNA also protects the integrity of DNA by preserving its structural shape. The discovery, involving the protein 53BP1, offers insight into understanding how cells maintain the integrity of DNA in the nucleus, which is critical for preventing diseases like premature aging and cancer.
Biostatisticians launch Cancer-Immu data portal for predicting response to immune checkpoint blockade immunotherapy
A new data portal called Cancer-Immu established by a team of biostatisticians can help cancer clinicians and researchers predict which patients will respond to immune checkpoint inhibitors. With data from 3,652 samples for 16 cancer types, Cancer-Immu is the largest immune checkpoint blockade-related data portal for exploring immunogenomic connections.
A new study shows that treatment with an immune-boosting protein called interleukin 7 (IL-7) in combination with radiation improves survival in mice with glioblastoma. The study in mice suggests promise for a phase 1/2 clinical trial that is investigating a long-acting type of IL-7 in patients with glioblastoma.
A new study has identified a new potential pathway for developing therapeutics that target Epstein-Barr virus (EBV).
Researchers report successfully removing the nucleus from a type of ubiquitous cell, then using the genetically engineered cell as a unique cargo-carrier to deliver therapeutics precisely to diseased tissues.
Characterizing the way, manner or pattern of evolution in tumors may be important for clinical forecasting and optimizing cancer treatment. Researchers are systematically examining how spatial structure influences tumor evolution. To do this the group developed a computational model with the flexibility to simulate alternative spatial structures and types of cell dispersal.
Researchers have developed an artificial intelligence platform to analyze potentially cancerous lesions in mammography scans to determine if a patient should receive an invasive biopsy. But unlike its many predecessors, the algorithm is interpretable, meaning it shows physicians exactly how it came to its conclusions.
The human immune system, that marvel of complexity, subtlety, and sophistication, includes a billion-year-old family of proteins used by bacteria to defend themselves against viruses, scientists have discovered.
A molecular feature in prostate cancer, called endogenous retroviral (ERV) RNA, has been found to have prognostic value and also distinguish differences between men of African and European or Middle Eastern ancestry, according to a new study. The team also identified ERV expression signatures that may be useful for identifying prostate cancer patients at greatest risk of progression regardless of ancestry, which may also extend to progression in other cancers.
Understanding how cells die is key to developing new treatments for many diseases, whether the goal is to make cancer cells die or keep healthy cells alive in the face of other illnesses, such as massive infections or strokes. Two new studies have identified a previously unrecognized pathway of cell death — named lysoptosis — and demonstrate how it could lead to new therapies for cervical cancer.
The discovery raises the possibility that some of the roughly two million new cases of colorectal cancer every year around the world originate from brief and seemingly mild food-poisoning events.
There are myriad reasons why cancers develop. By studying genes which are altered in people with lymphoma, a multidisciplinary team of researchers has identified a key mechanism involved in disease development. This signaling pathway, which the researchers describe in detail, controls the repair of DNA damage.
Multiple myeloma is a cancer of the bone marrow, with a life expectancy of less than 5 years post-diagnosis. Proteasome inhibitors, the therapeutic backbone of current treatments, are very effective in treating newly diagnosed cancers but resistance or intolerance to these molecules inevitably develop, leading to relapses. While studying a neglected tropical disease , Buruli ulcer, researchers discovered a novel therapeutic target for multiple myeloma that could allow to bypass this resistance.
When an individual suffers from cancer, the process of programmed cell death called apoptosis does not occur normally, permitting abnormal cells to thrive.
In a new study, researchers have identified the presence of a specific connection between a protein and an lncRNA molecule in liver cancer. By increasing the presence of the lncRNA molecule, the fat depots of the tumor cell decrease, which causes the division of tumor cells to cease, and they eventually die. The study contributes to increased knowledge that can add to a better diagnosis and future cancer treatments.
Tertiary lymphoid structures are formations that occur outside of the lymphatic system. They contain immune cells and are similar in structure and function to lymph nodes and other lymphoid structures. However, little is known about how tertiary lymphoid structures form. In a new article published in Immunity, Moffitt Cancer Center researchers report on the molecular and cellular mechanisms that control tertiary lymphoid structure formation within tumors.
Researchers identify signaling mechanisms in pancreatic cancer cells that could provide treatment targets
Scientists have provided new insights into molecular ‚crosstalk‘ in pancreas cancer cells, identifying vulnerabilities that could provide a target for therapeutic drugs already being studied in several cancers.
Acute myeloid leukemia (AML) is a cancer of white blood cells. Researchers discovered that AML cancer cells depend on a protein called SCP4 to survive. They think the previously little-known protein is involved in a metabolic pathway the cancer cells need to survive. SCP4 provides researchers with a potential new therapeutic approach for this aggressive cancer.
A new study reveals important insights into the molecular mechanisms that underpin the body’s natural defences against the development of skin cancer. The protein CSDE1 coordinates a complex chain of events that enable senescence in skin cells. The senescent cells act as a firewall against cancer, suppressing the formation of tumours. The findings are surprising because CSDE1 has been previously linked to driving the formation of cancers. The results offer new clues into the behavior of skin cancer at the cellular level, paving the way for potential new therapeutic targets to treat the disease.
Researchers reduce breast cancer metastasis in animal models by modifying tumor electrical properties
Researchers have found that manipulating voltage patterns of tumor cells — using ion channel blockers already FDA-approved as treatments for other diseases — can in fact significantly reduce metastasis in animal models of breast cancer.
A research team has successfully repurposed an approved drug ifenprodil, a vasodilator, to be used in combination with the FDA-approved first-line drug sorafenib for hepatocellular carcinoma (HCC) treatment. This study leveraged on their CombiGEM-CRISPR v2.0 screening platform1 to expedite the search among the many possible drug combinations to inhibit druggable targets in the genome for treating HCC.